# A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

> **NCT07553442** · PHASE2 · RECRUITING · sponsor: **Alnylam Pharmaceuticals** · enrollment: 93 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** ALN-AGT01 RVR
- **DRUG:** Placebo
- **DRUG:** Zilebesiran

## Key facts

- **NCT ID:** NCT07553442
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-27
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2026-05-14

## Collaborators

- Hoffmann-La Roche

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07553442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07553442, "A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07553442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*